SLN Earnings Date: Nov 5, 2026 (Estimated) — Silence Therapeutics plc
NASDAQ · Healthcare · Biotechnology
Updated
When is SLN's next earnings date?
Silence Therapeutics plc (SLN) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.11 on revenue of $113,400.
How did SLN do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Silence Therapeutics plc posted EPS of -$0.09 versus the -$0.14 estimate, a beat of 40.0%. Revenue was $0 against a $1.2M estimate. The stock's 1-day post-earnings move was +29.1%.
How much does SLN stock move after earnings?
SLN beat EPS estimates in 3 of its last 4 reported quarters. Over the last 8 reports the stock moved an average of 7.5% (up or down) in the day after earnings.
About Silence Therapeutics plc
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.14 | -0.09 | +40.00% | $0 | ✅ Beat | +29.12% | +14.81% | +14.56% |
| 2026-05-19 | Q1 2026 | -0.21 | -0.11 | +47.62% | $422,000 | ✅ Beat | -7.38% | +6.58% | +8.51% |
| 2026-03-05 | Q4 2025 | -0.43 | -0.27 | +37.21% | $34,000 | ✅ Beat | -4.84% | +20.76% | +2.77% |
| 2025-11-06 | Q3 2025 | -0.28 | -0.45 | -60.71% | $159,000 | ❌ Miss | +3.37% | +7.85% | +11.54% |
| 2025-02-27 | Q4 2024 | — | 0.27 | — | $24.9M | — | -1.05% | -0.84% | -22.64% |
| 2024-11-14 | Q3 2024 | — | -0.75 | — | $1.5M | — | -8.27% | -54.53% | -57.68% |
| 2024-08-15 | Q2 2024 | — | -0.42 | — | $754,497 | — | +3.14% | -2.58% | +14.94% |
| 2024-05-16 | Q1 2024 | — | -0.05 | — | $15.7M | — | +2.73% | +3.99% | -13.57% |
Showing last 8 quarters.